# Biliary Tract Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/biliary-tract-cancer

> 8 upcoming FDA catalysts in biliary Tract Cancer: Imfinzi® (durvalumab, AZN) on Jun to Sep 2028 (topline data readout); Imfinzi® (durvalumab, AZN) on June 2028 (primary completion); Ziihera® (zanidatamab, JAZZ) on December 2028 (primary completion); Ziihera® (zanidatamab, JAZZ) on Dec 2028 to Mar 2029 (topline data readout); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 2, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | completed | "NCT05771480 (Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05771480)) |
| Jun to Sep 2028 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06467357)) |
| June 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06467357)) |
| December 2028 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Biliary Tract Cancer | scheduled | "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282575)) |
| Dec 2028 to Mar 2029 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Biliary Tract Cancer | scheduled | "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282575)) |
| Jan to Apr 2029 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Biliary Tract Cancer | scheduled | "NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109779)) |
| January 2029 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Biliary Tract Cancer | scheduled | "NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109779)) |
| Jul to Oct 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221253)) |
| July 2029 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | scheduled | "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221253)) |

## Drugs

- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Ziihera® (zanidatamab)](https://sec-api.dev/pdufa/zanidatamab) (JAZZ)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/biliary-tract-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Biliary Tract Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/biliary-tract-cancer

```bibtex
@misc{secapidev_indications_biliary_tract_cancer_20261116,
  title        = {Biliary Tract Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/biliary-tract-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_biliary_tract_cancer_20261116","title":"Biliary Tract Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/biliary-tract-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
